Karyopharm Therapeutics
KPTI • NASDAQ
Karyopharm Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Richard A. Paulson, with a market cap of $184.0M.
Market Cap$184.0M
Employees325.0
CEORichard A. Paulson
CountryUnited States of America
Healthcare
Biotechnology
Next EarningsMay 11, 2026 · In 4 weeksQ1 2026
Financials
Karyopharm Therapeutics FAQ
Common questions about Karyopharm Therapeutics
Karyopharm Therapeutics is scheduled to report earnings for Q1 2026 on May 11, 2026. Analysts estimate revenue of $32.4M.
Karyopharm Therapeutics has approximately 325 employees.